The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.
 
Joel Hecht
Stock and Other Ownership Interests - Actym Therapeutics; Rafael Pharmaceuticals; Triumvira Immunologics, Inc
Consulting or Advisory Role - Agenus; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Medarex; Galvanize Therapeutics; MBQ Pharma; Revolution Medicines; Taiho Pharmaceutical; Xilio Therapeutics
Research Funding - A2 Biotherapeutics (Inst); Affini-T Therapeutics (Inst); Agenus (Inst); Amgen (Inst); Bold Therapeutics (Inst); Camurus (Inst); Cardiff Oncology (Inst); CG Pharmaceuticals (Inst); Crinetics Pharmaceuticals (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Janssen Oncology (Inst); Lyell Immunopharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neogene Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Regeneron (Inst); Revolution Medicines (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Xilio Therapeutics (Inst)
 
Elena Elez
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; cureteq; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; cureteq; Janssen; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); BioNTech (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; cureteq; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute; Roche; Sanofi; Seagan; SERVIER; Takeda
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Agenus; Amgen (I); EMD Serono; Merck Serono; Merus; Pfizer; Revolution Medicines; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Peter Gibbs
Honoraria - Bristol-Myers Squibb/Sanofi; Merck; MSD Oncology; Pierre Fabre; SERVIER
Consulting or Advisory Role - Haystack Oncology
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); GRAIL (Inst); Haystack Oncology (Inst); Merck Serono (Inst); Pierre Fabre (Inst); Roche (Inst); Servier (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Servier
 
Jenny Seligmann
Honoraria - GlaxoSmithKline; Merck Serono; Pierre Fabre; SERVIER; Takeda Science Foundation
Consulting or Advisory Role - Elevation Oncology; GlaxoSmithKline; Jazz Pharmaceuticals; Merck Serono; Sanofi; Takeda
Research Funding - GlaxoSmithKline (Inst); Merck Serono (Inst); Pierre Fabre (Inst)
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Hutchison MediPharma; Junshi Pharmaceuticals; Keymed Biosciences; MSD; QiLu Pharmaceutical
 
Kensei Yamaguchi
No Relationships to Disclose
 
Chao-Yuan Wang
No Relationships to Disclose
 
Hao Wei Teng
Consulting or Advisory Role - Johnson & Johnson
Speakers' Bureau - Johnson & Johnson
 
Leonardo Trani
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Honeylet Wortman-Vayn
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Zhengyu Jiang
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Brooke Diorio
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Patricia Lorenzini
Employment - Janssen Pharmaceuticals of Johnson and Johnson
 
Christine Baudelet
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Seema Sethi
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Mahadi Baig
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Chiara Cremolini
Honoraria - Amgen; Bayer; GlaxoSmithKline; Merck; Merck; MSD; Pierre Fabre; Roche; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Bicara Therapeutics; MSD; Nordic Bioscience; Pierre Fabre; Revolution Medicines; Roche; Rottapharm Biotech; Takeda
Speakers' Bureau - Merck; MSD; Pierre Fabre; SERVIER
Research Funding - Bayer; Merck; Roche; SERVIER